Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark
California
94560
United States
Tel: 510-742-3400
Fax: 510-742-3401
Website: http://www.revance.com/
Email: careers@revance.com
303 articles about Revance Therapeutics, Inc.
-
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
10/10/2022
Revance Therapeutics, Inc. announced today it will present two video abstracts featuring DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection at the American Society for Dermatologic Surgery (ASDS) Annual Meeting taking place in Aurora, CO, from October 6-10, 2022.
-
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
9/21/2022
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference.
-
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
9/19/2022
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY ™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal,
-
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
9/15/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an oral presentation by Dr. Atul Patel, JUNIPER clinical investigator, will take place on Friday, September 16 at 2:30 pm GMT+ 2 at the International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Madrid, Spain.
-
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
9/15/2022
Revance Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, at a price to the public of $25.00 per share.
-
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
9/13/2022
Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock.
-
Revance Announces Proposed Public Offering of Common Stock - September 12, 2022
9/12/2022
Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced a proposed underwritten public offering of $150 million of its common stock.
-
Brand Institute Partners on Brand Name and Nonproprietary Name Development for FDA Approved Injection for Frown Lines
9/12/2022
Brand Institute is proud to announce its work with Revance Therapeutics in developing the brand name DAXXIFY™, which was approved by the FDA on September 7, 2022.
-
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
9/8/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.
-
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
8/9/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
8/2/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market.
-
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
7/27/2022
Revance Therapeutics, Inc. today announced the presentation of six abstracts to be presented at the 2022 TOXINS International Conference on July 27-30, 2022 in New Orleans, Louisiana.
-
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
5/23/2022
Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago.
-
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
5/10/2022
Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
5/3/2022
Revance Therapeutics, Inc. today announced that the company will release first quarter financial results on Tuesday, May 10, 2022 after the close of market.
-
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
4/21/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
-
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
3/28/2022
Revance Therapeutics, Inc. today announced they will give one oral presentation and present one poster at the 2022 American Academy of Neurology Annual Meeting, taking place on April 2-7, 2022 in Seattle, Washington.
-
Money on the Move: March 16-22
3/23/2022
Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms. -
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
3/21/2022
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the closing of a $300 million note purchase agreement with funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm.
-
Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA
3/8/2022
Revance Therapeutics, Inc. today announced it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA.